5 completed, 3 terminated, 2 withdrawn, 1 not yet recruiting. 12 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 5, Terminated 3, Withdrawn 2, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 7 | Completed 3, Withdrawn 2, Terminated 1, Unknown 1 |
Follow Cancer of the Breast: new trials by email Literature Review of Cancer of the Breast trials Research Report on Cancer of the Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity 68Ga-Galmydar, PET/MRI, 18F-FDG - Lymphoma Cancer, Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 36 | 2026-11-01 | 2026-09-24 |
| A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer BC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tislelizumab) expansion cohort - Breast Cancer, Breast Tumor | Phase 1 / Phase 2 | Unknown | BriaCell Therapeutics Corporation | 18 | 2024-05-29 | 2024-08-26 |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC NUV-422, Fulvestrant - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Nuvation Bio Inc. | 2022-09-01 | 2023-07-11 | |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868, Olaparib, Enzalutamide - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvation Bio Inc. | 82 | 2022-03-29 | 2025-11-06 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NUV-422 - Glioma, Glioma, Malignant | Phase 1 | Terminated | Nuvation Bio Inc. | 74 | 2020-12-08 | 2023-07-14 |
| Real-time Intraoperative Breast Cancer Visualization for Margin Assessment LS301, Cancer Vision Goggles and standard fluorescence imaging systems, Surgery - Breast Cancer, Cancer of the Breast | Phase 1 / Phase 2 | Terminated | Samuel Achilefu | 9 | 2020-02-18 | 2025-08-17 |
| Bright Light on Fatigue in Women Being Treated for Breast Cancer Bright blue-green light using light visor cap, Dim red light using light visor cap, European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire - Breast Neoplasms, Breast Cancer | Phase 1 | Completed | Washington University School of Medicine | 19 | 2015-10-12 | 2017-09-25 |
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) Seviteronel - Cancer of the Breast, Breast Cancer | Phase 1 / Phase 2 | Completed | Innocrin Pharmaceutical | 175 | 2015-08-01 | 2019-02-01 |
| Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers Carboplatin, Eribulin, E7449 - Cancer of the Breast | Phase 1 / Phase 2 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2015-04-01 | 2015-08-25 | |
| Multipeptide Vaccine for Advanced Breast Cancer hTERT/Survivin Multi-Peptide Vaccine - Breast Neoplasm, Breast Cancer | Phase 1 | Completed | University of Pennsylvania | 11 | 2007-11-01 | 2016-09-29 |
| Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer Mycograb, Docetaxel - Cancer of the Breast | Phase 1 / Phase 2 | Completed | NeuTec Pharma | 20 | 2005-09-01 | 2008-07-15 |
| Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe) - Cancer of the Breast | Phase 1 / Phase 2 | Completed | University of Arkansas | 107 | 2004-09-01 | 2015-11-24 |
Breast Neoplasms (12) · Prostatic Neoplasms (2) · Prostatic Neoplasms, Castration-Resistant (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms, Male (1) · Carcinoma, Ductal (1) · Cardiotoxicity (1) · Cardiovascular Diseases (1) · Glioblastoma (1) · Glioma (1) · Hodgkin Disease (1) · Lymphoma, Non-Hodgkin (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
Breast Diseases (12) · Neoplasms (12) · Neoplasms by Site (12) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Neoplasms by Histologic Type (3) · Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Male Urogenital Diseases (2) · Neoplasms, Glandular and Epithelial (2) · Prostatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adenocarcinoma (1)
((ENB-3-isopropoxy-PIDMP)Ga(III)) (1) · Carboplatin (1) · Docetaxel (1) · Fluorodeoxyglucose F18 (1) · Fulvestrant (1) · Magnetic Resonance Imaging (1) · Poly(ADP-ribose) Polymerase Inhibitors (1) · Polysomnography (1) · Positron-Emission Tomography (1) · Surgical Procedures, Operative (1) · Telomerase (1) · cyclopropapyrroloindole (1) · efungumab (1) · enzalutamide (1) · eribulin (1)
Nuvation Bio Inc. (3) · Washington University School of Medicine (2) · BriaCell Therapeutics Corporation (1) · Innocrin Pharmaceutical (1) · NeuTec Pharma (1) · Samuel Achilefu (1) · The University of Texas Health Science Center at San Antonio (1) · University of Arkansas (1) · University of Pennsylvania (1)
United States (10) · Australia (1) · Poland (1) · Serbia (1)
Anna Pluzanska, MD (1) · Deborah Farr, M.D. (1) · Giuseppe Del Priore, MD, MPH (1) · Horng-Shiuann Wu, Ph.D., R.N. (1) · Kevin Fox, MD (1) · Pamela K Woodard, MD (1) · Samuel Achilefu, Ph.D. (1) · V. Suzanne Klimberg, M.D. (1) · Victoria Brown, BS (1) · Victoria Chua-Alcala, MD (1) · Virginia Kaklamani (1)
R01HL180913 (1)